Editing Functional: Pharmacological Management of LUTS (section)

===== Adverse events =====
* The clinical usefulness of available antimuscarinic agents is limited by their lack of selectivity
* '''The low persistence with prescribed anti-cholinergic therapy for OAB is due to lack of efficacy and adverse effects.'''
** '''The longest persistence has been reported for solifenacin'''
* '''<span style="color:#ff0000">Common side effects include:</span>'''
*# '''<span style="color:#ff0000">Dry mouth</span>''' (30% medication vs. 8% placebo)
*# '''<span style="color:#ff0000">Constipation</span>'''
*# '''<span style="color:#ff0000">Blurred vision</span>'''
*# '''<span style="color:#ff0000">CNS side effects (cognitive dysfunction, memory impairment, dizziness, fatigue, and headache)</span>'''
* '''<span style="color:#ff0000">Potential serious side effects are cardiac and include:</span>'''
*# '''<span style="color:#ff0000">Increases in heart rate</span>'''
*# '''<span style="color:#ff0000">Arrhythmia</span> (QT prolongation and induction of polymorphic ventricular tachycardia (torsades de pointes)'''
*#* '''QT prolongation is not related to muscarinic blockade''' but rather linked to inhibition of the hERG potassium channel in the heart. '''Some anti-cholinergic drugs may cause this, but this is not a class effect.'''